Current Controversies: Pro, Con, and Balance
Controversies in mucosal healing in ulcerative colitis
Article first published online: 11 FEB 2009
Copyright © 2009 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 15, Issue 5, pages 796–800, May 2009
How to Cite
Kane, S., Lu, F., Kornbluth, A., Awais, D. and Higgins, P. D.R. (2009), Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis, 15: 796–800. doi: 10.1002/ibd.20875
- Issue published online: 7 APR 2009
- Article first published online: 11 FEB 2009
- Manuscript Accepted: 15 DEC 2008
- Manuscript Received: 25 SEP 2008
- 2Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005; 100: 2478–2485., , , et al.Direct Link:
- 7Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: preliminary results from a prospective, multicenter study. In: Association AG, ed. Digestive Disease Week. Chicago; 2006: A197., , , et al.
- 11Increased inflammatory activity is an independent risk factor for dysplasia and colorectal cancer in ulcerative colitis: a case-control analysis with blinded prospective pathology review. Digestive Disease Week. Gastroenterology; 2005: A103., , , et al.
- 12Increased degree of histological inflammation predicts colectomy and hospitalization in patients with ulcerative colitis. Gastroenterology: Digestive Disease Week 2007: A103., , , et al.
- 19Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol. 2005; 100: 355–361., , , et al.Direct Link: